SHORT MINI-FUTURE - GENMAB | Delayed Deutsche Boerse AG 19:02:09 22/05/2024 BST | ||
| 27.11 EUR | -2.17% |
|
| Current month | -5.31% | ||
| 1 month | -0.88% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GENMAB A/S
| Date | Price | Change |
|---|---|---|
| 22/05/24 | 27.11 | -2.17% |
| 21/05/24 | 27.71 | +1.76% |
| 17/05/24 | 27.23 | -0.15% |
| 16/05/24 | 27.27 | +1.34% |
| 15/05/24 | 26.91 | -2.68% |
Delayed Quote Deutsche Boerse AG
Last update May 22, 2024 at 07:02 pm
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | GENMAB A/S |
| Issuer | 
Vontobel
|
| WKN | VV9GS9 |
| ISIN | DE000VV9GS91 |
| Date issued | 10/11/2022 |
| Strike | 4,087 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 14.71 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 30.22 € |
|---|---|
| Lowest since issue | 10.54 € |
| Spread | 0.69 € |
| Spread % | 2.49% |
Company Profile
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Sector
-
Consensus: Genmab A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
2,055
DKK
Average target price
2,466
DKK
Spread / Average Target
+19.99%
- Stock Market
- Certificates
- Certificat
